Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 4505-4505 ◽  
Author(s):  
M. Aitchison ◽  
C. A. Bray ◽  
H. Van Poppel ◽  
R. Sylvester ◽  
J. Graham ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Risk Of Relapse

scholarly journals Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

2018 ◽  
Vol 25 (4) ◽  
pp. 1165-1173 ◽  
Author(s):  
Daniel J. George ◽  
Jean-Francois Martini ◽  
Michael Staehler ◽  
Robert J. Motzer ◽  
Ahmed Magheli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase Iii ◽  
Phase Iii Trial

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib

2018 ◽  
Vol 24 (18) ◽  
pp. 4407-4415 ◽  
Author(s):  
Brian I. Rini ◽  
Bernard Escudier ◽  
Jean-Francois Martini ◽  
Ahmed Magheli ◽  
Christer Svedman ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Recurrence Score ◽  
Phase Iii ◽  
Phase Iii Trial
Sign in / Sign up

Export Citation Format

Share Document